News

The Vaxinano's technology, high hope for Covid-19 vaccine (Le MQ. & al., <cite>Int. J. Pharm. 2020</cite>)

The Vaxinano's technology, high hope for Covid-19 vaccine (Le MQ. & al., Int. J. Pharm. 2020)

Thursday, April 16th 2020
Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission
Recent publications described that influenza Vaxinano's vaccine administered via a spray by the nasal route allows strong T-cell activation and production of sIgA in the mucosa (Bernasconi V. & al., Front. Immunol. 2018). In this new publication (Le MQ. & al., Int. J. Pharm. 2020) we demonstrated that Vaxinano's vaccine also inhibits the transmission of the viral infection.


These results are of main importance in the global context of the Covid-19 since the Vaxinano's technology is ready to be transposed to this very infectious coronavirus.

Vaxinano is starting collaborations on the rapid development of an anti-Covid-19 vaccine. New collaborators are welcome to contact us.



For more information: Le MQ. & al., Effective Nanoparticle-Based Nasal Vaccine against Latent and Congenital Toxoplasmosis in Sheep. Front. Immunol. 2020.
Read the publication
< Back